U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 9 of 9 results

Status:
US Approved Rx (1998)
First approved in 1995

Class (Stereo):
CHEMICAL (ABSOLUTE)



Lamivudine is a reverse transcriptase inhibitor used alone or in combination with other classes of anti-human immunodeficiency virus (HIV) drugs in the treatment of HIV infection. This molecule has two stereo-centers, thus giving rise to four stereoi...
Status:
US Previously Marketed
First approved in 2011

Class (Stereo):
CHEMICAL (MIXED)



Boceprevir (trade name Victrelis) is first-generation, selective, small molecule inhibitor of the non-structural serine protease (NS3) and NS4A polypeptide complex (NS3/NS4A) and is a direct acting antiviral drug against the hepatitis C virus. It is ...
Status:
US Previously Marketed
First approved in 2006

Class (Stereo):
CHEMICAL (ABSOLUTE)

Targets:


Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo (Europe) and Tyzeka (United States). Clinical trials have shown it to be significant...
Status:
US Approved Rx (2002)
First approved in 2002

Class:
PROTEIN

Status:
US Approved Rx (1986)
First approved in 1986

Class:
PROTEIN

Status:
US Approved Rx (2018)
First approved in 2005

Class (Stereo):
CHEMICAL (ABSOLUTE)

Targets:

Conditions:

BARACLUDE® is the tradename for entecavir, a guanosine nucleoside analogue with selective activity against hepatitis B virus (HBV). It inhibits all three steps in the viral replication process. By competing with the natural substrate deoxyguanosine t...
Status:
US Approved Rx (2013)
First approved in 2002

Class (Stereo):
CHEMICAL (ACHIRAL)



The potential antiviral effect of adefovir, an acyclic nucleoside phosphonate analog of 2′-deoxyadenosine monophosphate, was first studied by Holý and De Clercq in 1980s. Adefovir is an acyclic nucleotide analog of adenosine monophosphate which is ph...
Status:
US Approved Rx (2018)
First approved in 2001

Class (Stereo):
CHEMICAL (ABSOLUTE)



CMX157 is a lipid (1-0-hexadecyloxypropyl) conjugate of the acyclic nucleotide analog tenofovir (TFV) with activity against both wild-type and antiretroviral drug-resistant HIV strains, including multidrug nucleoside/nucleotide analog-resistant virus...
Status:
US Previously Marketed
First approved in 2015

Class (Stereo):
CHEMICAL (ABSOLUTE)



Daclatasvir (BMS-790052) is a direct-acting antiviral agent against Hepatitis C Virus (HCV) used for the treatment of chronic HCV genotype 3 infection. Daclatasvir prevents RNA replication and virion assembly by binding to NS5A, a nonstructural phosp...